India’s Glenmark Pharma (BSE: 532296) on Thursday said it has received final approval from the US Food and Drug Administration to manufacture and market potassium chloride extended release capsules and oral contraceptive norethindrone acetate and ethinyl estradiol tablets in the US market.
The company said the approved product has an estimated US market size of $74.1 million for the 12 months ended November 2015, citing IMS data.
Glenmark Pharma has also received approval for norethindrone acetate and ethinyl estradiol tablets. It is a generic version of US-based Warner Chilcott's oral contraceptive drug Leostrin21.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze